H.B. Fuller is showing improving margins, solid cash generation, and a credible medical adhesives growth story. Leverage and acquisition integration risk keep the stock in Hold territory despite attractive valuation.
H.B. Fuller Company (FUL) offers a credible medium-term improvement story built on pricing power, restructuring savings, and a shift toward medical adhesives. The second quarter of fiscal 2026 produced revenue of $950.3M, up 5.8% year over year, adjusted EBITDA of $181M, up 9%, and adjusted EPS of $1.41, up 19%. Organic revenue growth was 2.6%, with pricing contributing 3.0% and volume declining 0.4%.
The operating performance is stronger than the headline organic growth suggests. Adjusted gross margin expanded to 34.2% from 32.2%, while management raised fiscal 2026 adjusted EPS guidance to $4.60 to $4.90 and adjusted EBITDA guidance to $650M to $675M. Analysts estimate EPS of $4.85 in fiscal 2026, rising to $6.04 by fiscal 2028.
The counterweight is leverage. FUL carried $2.07B of debt and $114.1M of cash at the end of the second quarter, with net debt at 3.1 times adjusted EBITDA. The proposed Advanced Medical Solutions acquisition would push pro forma net leverage to approximately 4.0 times before synergies. That makes execution important precisely when the company is asking investors to pay for a higher-margin future.
The investment conclusion is Hold for a moderate-risk investor. FUL has attractive cash generation, a forward P/E of 9.2 times, and a 14.8% free cash flow yield, but the balance sheet and acquisition integration risk limit the margin of safety. The report's single fair value estimate is $60.00 per share.
H.B. Fuller (FUL) is a specialty adhesives and sealants company founded in 1887 and headquartered in Saint Paul, Minnesota. It formulates and manufactures adhesives, sealants, coatings, polymers, tapes, encapsulants, additives, and related specialty chemical products.
Fiscal 2025 revenue was $3.47B. The Hygiene, Health and Consumable Adhesives segment represented $1.55B, or 44.7% of revenue. Engineering Adhesives contributed $1.06B, or 30.6%, while the construction-related segment contributed $860.0M, or 24.8%. The company reorganized its segment structure in fiscal 2025, with Building Adhesive Solutions replacing the prior construction label in subsequent operating commentary.
FUL's business model is formulation-led rather than purely volume-led. Customers buy an adhesive that must meet performance, quality, regulatory, and process requirements. That gives technical service and application knowledge a larger role than a simple commodity price comparison, although raw materials still represented approximately 75% of cost of sales in fiscal 2025.
Hygiene, Health and Consumable Adhesives, or HHC, remains the largest segment. In the second quarter of fiscal 2026, revenue reached $421.9M, up 6.1% year over year, with organic growth of 3.0%. Medical, tape and label, and end-of-line packaging were stronger areas, while flexible packaging weakened. Management reported an EBITDA margin of 17.9%, up 230 basis points year over year.
Engineering Adhesives generated second-quarter revenue of $283.2M, up 2.5% year over year. Organic revenue declined 1.0% including the exited solar business, but organic revenue increased approximately 5% excluding solar. Aerospace grew more than 30% organically, while electronics and general industries grew at double-digit rates. Automotive declined at a mid-single-digit rate in all three regions.
Building Adhesive Solutions was the strongest broad segment in the quarter. Revenue reached $245.2M, up 9.4%, with organic growth of 6.2%. Glass, infrastructure, and mechanical applications drove both pricing and volume. EBITDA increased 10% year over year, showing that the segment's growth was not simply a price pass-through exercise.
Geographic performance also favored the international footprint. EIMEA organic revenue increased 8%, and Asia Pacific organic revenue increased 10% excluding solar. Americas organic revenue grew 1%, with Engineering Adhesives and Building Adhesive Solutions each growing 4% organically. The geographic split shows where FUL's sourcing and customer relationships are providing the greatest operating leverage.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
FUL's most important growth platform is its medical adhesive business rather than a single branded product. The existing medical platform covers topical and internal adhesive applications, medical device assembly, medical tapes and wearables, and surgical drapes and gowns.
Management described medical as a core strategic market because regulatory approvals, clinical validation, and customer qualification create barriers to entry. FUL currently serves a medical addressable market of approximately $6B growing about 8% annually. That growth rate is materially stronger than the company's fiscal 2026 organic revenue target of low-single-digit growth.
The proposed acquisition of Advanced Medical Solutions would expand FUL's medical adhesives revenue from $68M to approximately $370M on a pro forma basis using 2025 results. AMS adds surgical adhesives, tapes and dressings, mechanical closures, and formulated biosurgicals. The combined platform is expected to generate EBITDA margins above 30% by 2030.
The product logic is strongest in tapes and dressings, where FUL's upstream adhesive materials can be integrated into AMS finished products. That vertical connection gives the combined company a chance to capture both material margin and supply-chain benefits. The proposed transaction also expands the company's medical addressable market to $95B.
FUL's competitive advantage rests on formulation expertise, customer-specific application knowledge, and global supply assurance. Its 2025 10-K identifies product performance, supply assurance, technical service, quality, price, and customer service as the key competitive factors.
The company operates local laboratories in each region and coordinates platform development through a global laboratory network. Its research and development work includes new polymers, new formulations, new applications for existing products, and manufacturing improvements. This approach links innovation to customer processes rather than treating research as a stand-alone expense.
Medical adds a second layer of defensibility. AMS brings regulatory, clinical, quality, and certification capabilities, while FUL brings customer-led development, material science, and global manufacturing. Management also reported that EBITDA for 11 acquisitions completed since 2023 has grown approximately 55%, with margins expanding by more than 1,000 basis points.
The moat is real but not absolute. The 10-K states that much of the technology used in the company's products and manufacturing processes is available in the public domain. FUL relies on trade secrets, patents, trademarks, customer relationships, and technical service to protect its position. In adhesives, the practical switching cost often comes from re-formulation, re-testing, and customer re-approval rather than from a single patent.
FUL's operating footprint is designed around regional production. The 2025 10-K reports sales offices and manufacturing plants in 24 countries outside the United States, with satellite sales offices in nine additional countries. Most products sold within a region are produced within that region, limiting dependence on long-distance interregional shipments.
Raw materials remain the central operating exposure. FUL uses tackifying resins, polymers, synthetic rubbers, vinyl acetate monomer, plasticizers, and other petroleum- and natural-gas-based derivatives. Management generally avoids sole-source supplier arrangements, but supply and demand conditions still influence both cost and availability.
The second-quarter transcript described a petrochemical supply disruption linked to conflict in the Middle East. Management said pricing actions were ramping, global sourcing was maintaining supply continuity, and raw material costs were unlikely to return quickly to pre-disruption levels. Q2 adjusted gross margin of 34.2%, up 200 basis points, shows that pricing and restructuring are currently offsetting the pressure.
Working capital execution improved during the quarter. Net working capital fell to 16.4% of annualized net revenue, down 260 basis points sequentially. Operating cash flow reached $121M, described as a record second quarter. The improvement matters because the proposed AMS transaction depends on cash generation to reduce leverage after closing.
The global adhesives and sealants market was estimated at $77.1B in 2025 and is projected to reach $123.2B by 2033, representing a 6.0% compound annual growth rate. FUL's product portfolio spans hot melts, water-based, reactive polyurethane, silicone, cyanoacrylate, UV-cured, epoxy, and other chemistries, giving it exposure to multiple growth pockets rather than one formulation family.
Demand is linked to packaging, hygiene, construction, electronics, medical devices, aerospace, transportation, and infrastructure. In Q2 fiscal 2026, FUL demonstrated that mix matters: aerospace grew more than 30% organically, electronics and general industries grew double digits, and Building Adhesive Solutions grew 6.2% organically. Automotive, by contrast, declined at a mid-single-digit rate in each region.
The medical market is the most attractive part of the portfolio from a growth and resilience perspective. FUL describes medical demand as largely non-discretionary and supported by procedure volumes, minimally invasive techniques, and demand for improved patient outcomes. The AMS transaction would give FUL a larger position in that market while increasing exposure to regulated, higher-margin applications.
Sustainability is also changing product requirements. The 10-K describes ongoing work on adhesives and sealants that support customers' sustainability programs, while industry research identifies low-VOC, water-based, high-solids, and bio-based formulations as important development areas. These opportunities support innovation spending, but they also raise regulatory and reformulation costs.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
FUL sells primarily to business customers that incorporate adhesives into manufacturing or construction processes. Its customer base includes food and beverage manufacturers, hygiene product companies, packaging converters, appliance makers, electronics manufacturers, automotive companies, aerospace and defense contractors, construction-material producers, roofing-system suppliers, furniture makers, and medical businesses.
No single customer represented more than 10% of consolidated net revenue in fiscal 2025. That concentration profile reduces the risk that one customer loss would reset the entire earnings model. The more important customer risk is qualification and specification pressure: a customer can remain loyal when performance and supply reliability matter, but can still negotiate aggressively on price.
The sales model combines direct commercial relationships with distributors. FUL's technical support and customer-specific formulation work increase its role in the production process. That embedded position supports recurring demand, while the exposure to construction, automotive, packaging, and industrial production leaves revenue sensitive to economic cycles.
FUL competes with multinational suppliers such as Henkel, Sika, Arkema through Bostik, 3M, RPM International, Dow, BASF, Huntsman, Wacker, and Illinois Tool Works, as well as regional and specialty formulators. The 10-K separates the competitive field into broad multinational companies and narrower regional suppliers.
Henkel and Arkema provide large global adhesive platforms, Sika has major construction and sealant exposure, 3M competes in tapes and industrial bonding, and RPM has significant construction and sealant exposure. FUL's stated advantage is focus: management describes the company as a pure-play adhesives provider with broad technology coverage and a global operating footprint.
The second-quarter results show where FUL competes effectively. Management cited supply assurance during a disruption, positive pricing across segments, and strong growth in aerospace, electronics, infrastructure, and mechanical applications. Those results support the company's claim that reliability and technical service can matter alongside price.
Scale remains the main competitive limitation. Larger peers can bring greater procurement leverage, broader research budgets, and more extensive customer coverage. FUL's response is to concentrate on formulation niches, acquire specialized businesses, and use its global sourcing platform to defend margins.
The immediate macro issue is input-cost volatility. FUL's 10-K states that a 1% change in raw material costs would have changed fiscal 2025 net income by approximately $12.6M, or $0.23 per diluted share. Because raw materials represent approximately 75% of cost of sales, pricing execution is a central earnings variable.
Management said the Middle East-related supply disruption had reset the industry's cost structure and that intermittent shortages could persist even after activity in the Strait normalizes. That assessment supports the company's fiscal 2026 pricing actions, but it also means volume and customer affordability remain important constraints.
Foreign exchange adds another variable. Currency reduced fiscal 2025 revenue by approximately $20.1M, and a 1% change in cost of sales from foreign exchange would have changed net income by approximately $9.1M, or $0.17 per diluted share. FUL's regional manufacturing network limits some exposure, but the company remains globally diversified.
Regulation creates both opportunity and cost. FUL operates under EPA, EU REACH, environmental, worker safety, anti-corruption, and data protection rules. The company estimates approximately $22.6M of environmental compliance expenditures over the next two years, including $2.6M of capital expenditures. Medical expansion adds further regulatory value through AMS expertise, but also increases the importance of quality and certification execution.
FUL ended the quarter with $2.07B of debt, $114.1M of cash, and net debt at 3.1x adjusted EBITDA, while the proposed Advanced Medical Solutions deal would lift pro forma leverage to about 4.0x before synergies.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Second-quarter revenue rose 5.8% to $950.3M, adjusted EBITDA climbed 9% to $181M, and gross margin expanded to 34.2% from 32.2% as pricing more than offset a small volume decline.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management raised fiscal 2026 adjusted EPS guidance to $4.60-$4.90 and EBITDA guidance to $650M-$675M, while analysts see EPS reaching $6.04 by fiscal 2028.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →FUL trades at 9.2x forward earnings with a 14.8% free cash flow yield, leaving valuation attractive but not enough to fully offset balance-sheet and deal risk.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report's single fair value estimate is $60.00 per share, which supports a Hold view given the upside from current cash generation and the downside from leverage.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →H.B. Fuller (FUL) is executing better operationally than its modest organic growth rate implies. Q2 fiscal 2026 delivered 200 basis points of adjusted gross margin expansion, 9% adjusted EBITDA growth, 19% adjusted EPS growth, and record second-quarter operating cash flow of $121M. The company's sourcing network and pricing actions are producing tangible results during a difficult input-cost environment.
The medical strategy provides the strongest long-term upside. The proposed AMS transaction would expand the medical adhesive platform from $68M to approximately $370M of pro forma revenue, add an addressable market reaching $95B, and create identified synergies of $55M. The strategic logic is strong because AMS adds regulated medical applications while FUL contributes formulation, sourcing, and manufacturing capabilities.
The main risk is financial rather than strategic. FUL starts with $2.07B of debt, $114.1M of cash, and 3.1 times net leverage. Financing AMS with approximately $1B of incremental debt would raise pro forma leverage to about 4.0 times before synergies. That structure makes cash conversion and integration discipline more important than a simple low P/E screen suggests.
A Hold recommendation therefore best fits the evidence. FUL has the earnings momentum, customer relationships, margin opportunity, and medical exposure to build shareholder value, but the stock deserves a higher rating only after the acquisition risk is matched by visible deleveraging and sustained cash generation.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
H.B. Fuller Company (FUL) slipped after a mixed quarter that paired an adjusted EPS beat with a slight revenue miss. Our deep dive looks beyond the headline, covering margin expansion, segment trends, guidance, leverage, and why investors still see acquisition and execution risk.
H.B. Fuller Company (FUL) slips 1.1% even after posting earnings beats, as investors weigh the latest results against broader market sentiment.
A busy earnings calendar spans capital markets, travel, autos, semiconductors, and consumer brands. Micron, Carnival, Jabil, and Accenture headline the week, with several companies topping EPS estimates even as many stocks still trade below key moving averages.